García-Frade-Ruiz LF, Solís-Ayala E

Language: Spanish
References: 22
Page: 171-178
PDF size: 683.49 Kb.

ABSTRACT

Without a doubt, one of the greatest advances in medicine in recent years has been related to coagulation, not only understanding the etiology of thrombogenesis, but also in the development of new antithrombotic drugs. Direct inhibitors of thrombin such as dabigatran shows a straight and a dose dependent relationship with Ecarin clotting time; the measurement of anti-Xa activity is the best way of monitor direct inhibitors of X factor, such as rivaroxaban and apixaban. However the several advantages of the new anticoagulants compared to enoxaparin, seems to be not enough for putting aside enoxaparin as the first choice medication in the prevention of VTE in mayor orthopedic surgery. As atrial fibrillation increases its incidence with age, new anticoagulants became a good choice of treatment in the patient with multiple pathologies due to its low pharmacological interactions, and also, they are beginning to overcome warfarin for this pathology even in guidelines.

REFERENCES

1. García-Frade. Agentes antitrombóticos. En: Manual de trombosis y terapia antitrombótica. García-Frade LF. 2ª ed. México: Alfil, 2011.

2. Palladino M, Thomson L, Swift B, et al. Implementing the new oral anticoagulants into the hospital formulary. Am J Hematol 2012.

3. Ordovás JP, Climent E, Jover A. Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales. Farm Hosp 2009;33(3):125-133.

4. Lassen M, Raskob G, Gallus A, et al. Apixaban versus enoxaparina for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010;375:807-815.

5. Eriksson B, Borris L, Friedman R, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.

6. Kakkar A, Brenner B, Dahl O, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet 2008;372:31-39.

7. Lassen M, Ageno W, Borris L, et al. Rivaroxaban versus enoxaparina for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786.

8. Turpie A, Bauer K, Davidson B, et al. Comparison of rivaroxaban-an oral direct Factor Xa inhibitor-and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study). European Federation of National Associations of Orthopedics and Traumatology 2008 Meeting, 29 May-1 June 2008, Nice, France Abstract F85.

9. Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferiority trial. Lancet 2007;370:949-956.

10. Eriksson B, Dahl O, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.

11. Wittkowsky A. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010;29:182-91.

12. Guyatt G, Akl E, Crowther M, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141;7S-47S.

13. Connolly S, Ezekowitz M, Phil, et al. Dabigatran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 2009;361:1131-1159.

14. Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011.

15. Granger C, Alexander J, McMurray J, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011.

16. Tendera M, Syzdó M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012;19: 4-10.

17. Tan Ru San, Mark Yan Yee Chan, TeoWee Siong, et al. Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis 2012;1-10.

18. Banerjee A, Lane D, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatrán, rivaroxabán, apixaban) versus no treatment in a “real world” atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:1-6.

19. Hvilsted L, Bjerregaard T, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for Stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012;345:e7097.

20. The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010.

21. Schulman S, Kearon C, Kakkar A, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009;361:2342-2362.

22. Eikelboom J, Quinlan D, Connolly S, et al. Dabigatran efficacysafety assessment for stroke prevention in patients with atrial fibrillation. J Thromb Haemost 2012;10:966-968.